Medical cannabis lozenges and compositions thereof
View Patent ↗A method for optimizing the therapeutic effects provided by CBD on the one hand, and the psychoactive effects provided by THC on the other hand, in a sublingual medicament, the method includes the steps of obtaining a concentrated extract of cannabis in which the concentration of CBD is known and the concentration of THC is known, formulating a hydrophilic mixture containing ingredients such as sugar, corn syrup, xylitol, purified water, organic flavorings, coconut oil, and concentrated extract of cannabis , wherein the amount of CBD is as high as possible and where the amount of THC is precisely controlled, forming lozenges, and administering the medicament.
1. A lozenge consisting essentially of extracted cannabis sativa oil, extracted cannabis indica oil, and xylitol, wherein the extracted cannabis sativa oil and the extracted cannabis indica oil comprise cannabidiol and tetrahydrocannabinol.
2. The lozenge of claim 1 having a mass of between 2 grams and 15 grams.
3. The lozenge of claim 2 containing a minimum of 25 mg of cannabidiol.
4. The lozenge of claim 2 containing a maximum of 40 mg of tetrahydrocannabinol.
5. A lozenge consisting essentially of extracted cannabis sativa oil, extracted cannabis indica oil, and xylitol, wherein the extracted cannabis sativa oil and the extracted cannabis indica oil comprise cannabidiol and tetrahydrocannabinol, the lozenge containing a minimum of between about 0.1667% by weight and about 1.25% by weight of cannabidiol.
6. A lozenge consisting essentially of extracted cannabis sativa oil, extracted cannabis indica oil, and xylitol, wherein the extracted cannabis sativa oil and the extracted cannabis indica oil comprise cannabidiol and tetrahydrocannabinol, the lozenge containing a maximum of between about 0.2667% by weight and about 2.00% by weight of tetrahydrocannabinol.
7. The lozenge of claim 1 further consisting essentially of an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof.
8. A method for minimizing the psychoactive effects of tetrahydrocannabinol in a human which is administered a sublingual lozenge containing extracted cannabis sativa oil and extracted cannabis indica oil, the method consisting essentially of: a) formulating the lozenge with extracted cannabis sativa oil, extracted cannabis indica oil, and xylitol, wherein the extracted cannabis sativa oil and the extracted cannabis indica oil comprise cannabidiol and tetrahydrocannabinol; and b) administering the lozenge sublingually to a human until the lozenge is dissolved in the human.
9. The method of claim 8 , wherein the step of formulating the lozenge is maximizing the cannabidiol concentration.
10. The method of claim 8 , wherein the step of formulating the lozenge is minimizing the tetrahydrocannabinol concentration.
11. The method of claim 8 , wherein the step of formulating the lozenge is maximizing the tetrahydrocannabinol concentration.
12. A lozenge for sublingual administration of a medicament consisting essentially of heat decarboxylated extracted cannabis sativa oil, heat decarboxylated extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, wherein the lozenge contains a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol.
13. A lozenge for sublingual administration of a medicament consisting essentially of heat decarboxylated extracted cannabis sativa oil, heat decarboxylated extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge containing a minimum of between about 0.1667% by weight and about 1.25% by weight of cannabidiol and a maximum of between about 0.2667% by weight and about 2.00% by weight of tetrahydrocannabinol.
14. A method for minimizing the psychoactive effects of tetrahydrocannabinol in a therapeutic treatment of a human patient, the method consisting essentially of:
a) formulating a lozenge consisting essentially of heat decarboxylated extracted cannabis sativa oil, heat decarboxylated extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, wherein the lozenge contains a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol; and
b) administering the lozenge sublingually to a human until the lozenge is dissolved in the human, thereby minimizing the psychoactive effects of tetrahydrocannabinol on the patient.
15. A method for minimizing the psychoactive effects of tetrahydrocannabinol in a therapeutic treatment of a human patient, the method consisting essentially of: a) formulating a lozenge consisting essentially of heat decarboxylated extracted cannabis sativa oil, heat decarboxylated extracted cannabis indica oil, xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge containing a minimum of between about 0.1667% by weight and about 1.25% by weight of cannabidiol and a maximum of between about 0.2667% by weight and about 2.00% by weight of tetrahydrocannabinol; and b) administering the lozenge sublingually to a human until the lozenge is dissolved in the human, thereby minimizing the psychoactive effects of tetrahydrocannabinol on the patient.
16. A method of preparing a lozenge for sublingual administration of a medicament containing cannabidiol and tetrahydrocannabinol to a human patient, the method comprising the following steps: selecting a sativa cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known; selecting an indica cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known; heating the sativa cannabis and the indica cannabis to a temperature not higher than 190 degrees Fahrenheit for a period of time sufficient to cause decarboxylation of the cannabinoids contained therein; extracting the sativa cannabis and the indica cannabis ; and formulating the lozenge with xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge having a mass of between 2 grams and 15 grams, whereby the lozenge contains a minimum of 25 mg of cannabidiol and a maximum of 40 mg of tetrahydrocannabinol.
17. A method of preparing a lozenge for sublingual administration of a medicament containing cannabidiol and tetrahydrocannabinol to a human patient, the method comprising the following steps: selecting a sativa cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known; selecting an indica cannabis in which the amount of cannabidiol and tetrahydrocannabinol is known; heating the sativa cannabis and the indica cannabis to a temperature not higher than 190 degrees Fahrenheit for a period of time sufficient to cause decarboxylation of the cannabinoids contained therein; extracting the sativa cannabis and the indica cannabis ; and formulating the lozenge with xylitol and an ingredient selected from the group consisting of sugar, corn syrup, flavorings, coloring agents, coconut oil, purified water and mixtures thereof, the lozenge containing a minimum of between about 0.1667% by weight and about 1.25% by weight of cannabidiol and a maximum of between about 0.2667% by weight and about 2.00% by weight of tetrahydrocannabinol.